International Journal of Drug Policy

Papers
(The H4-Index of International Journal of Drug Policy is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Publisher's Note274
Editorial Board106
Older age at smoking initiation predicts successful cessation in adults who smoke: A prospective study75
Opioid prescribing restrictions and opioid use among the Louisiana Medicaid population74
Doing more with less: A proposal to advance cigarette packaging regulations in the United States65
Editorial Board59
Editorial Board58
Editorial Board57
Editorial Board56
Ecological dimensions of cannabis regulation in the Rif, Morocco52
The social-structural contexts of cannabis consumption and harm reduction among young Nigerian women51
Quasi-experimental study on the impact of local smoke-free policies on smoking among Indonesian adults: Evidence from repeated national health surveys48
Increased solitary drug use during COVID-19: An unintended consequence of social distancing47
Contentious legality in decentralized governance: The rise and decline of cannabis social clubs in Spain46
Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States46
Leveraging pooled medical examiner records to surveil complex and emerging patterns of polysubstance use in the United States44
International property rights for Cannabis landraces and terroir products. The case of Moroccan Cannabis and hashish42
Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts42
Barriers to evidence-based alcohol policies in France: Insights from interviews with parliament members42
Incarceration history, antiretroviral therapy, and stigma: A cross-sectional study of people with HIV who inject drugs in St. Petersburg, Russia41
Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers40
Identifying barriers and enablers to opt-out hepatitis C virus screening in provincial prisons in Quebec, Canada: A multilevel, multi-theory informed qualitative study with correctional and healthcare39
Co-designing the INHSU Prisons Hepatitis C Advocacy Toolkit using the Advocacy Strategy Framework39
The introduction of fentanyl on the US–Mexico border: An ethnographic account triangulated with drug checking data from Tijuana38
Opioid agonist therapy engagement and crystal methamphetamine use: The impact of unregulated opioid use in Vancouver, Canada38
Bridging the gap: An environmental scan of post-overdose program features and evaluation measures37
Impact of health policies on opioid tapering and discontinuation among patients receiving long-term opioid therapy for chronic noncancer pain37
Adapting the WHO MPOWER framework for E-cigarettes: Qualitative insights from South Korea35
Seizure-to-market ratios and the resilience of the drug markets in France (2010–2023)35
A comprehensive analysis of jurisdiction-specific laws related to scheduling or required prescription drug monitoring of gabapentin in the United States, 2016–202435
Social-spatial network structures among young urban and suburban persons who inject drugs in a large metropolitan area34
‘Choice’ of social media platform or encrypted messaging app to buy and sell illegal drugs34
A content analysis of cannabis edibles package marketing in the United States33
0.13291096687317